Bristol-Myers Squibb Company (BMY) Total liabilities 2016–2025
Bristol-Myers Squibb Company (BMY) total liabilities at each fiscal year-end, per SEC filings.
$71.5BFY2025 · since FY2016: $17.4B → $71.5B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $71.5B | -6.1% |
| FY2024 | $76.2B | +16.1% |
| FY2023 | $65.7B | -0.0% |
| FY2022 | $65.7B | -10.4% |
| FY2021 | $73.3B | -9.0% |
| FY2020 | $80.6B | +3.0% |
| FY2019 | $78.2B | +275.1% |
| FY2018 | $20.9B | -3.9% |
| FY2017 | $21.7B | +25.0% |
| FY2016 | $17.4B | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice